{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ACB",
  "name": "Aurora Cannabis Inc.",
  "url": "https://frontierpicks.com/dossiers/ACB/",
  "json_url": "https://frontierpicks.com/dossiers/ACB.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Frame flipped 2026-08-11: Curaleaf's unsolicited proposal — 0.3463 CURLF shares + US$0.75 cash, implied US$4.00, capped at US$5.00 — turned a broken Canadian LP into a live take-over situation. No formal bid has been commenced, the board formed a special committee, and the 2026-08-14 close of $3.68 already carries most of the announced premium at RSI 79.7.",
  "invalidation_trigger": "A weekly close below $3.05 gives back the bulk of the 2026-08-11 bid gap and reads as the market pricing a failed process back toward the US$2.75 pre-announcement 30-day VWAP; reinforced if Curaleaf's stated intention lapses with no formal bid circular mailed, or Aurora's directors' circular rejects with no raised offer.",
  "catalyst_date": "2026-08-17",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "semi-foundry-equipment",
    "cannabis-reclassification"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Canadian issuer: any Curaleaf offer is a take-over bid under NI 62-104 (105-day minimum deposit period, reducible to no fewer than 35 days with target-board consent).",
    "Consideration is mostly Curaleaf subordinate voting shares, which trade on the TSX and OTCQX rather than a US national exchange due to US plant-touching operations.",
    "As of 2026-08-11 no formal bid had been commenced - Curaleaf's release states an intention only, with no assurance an offer is ultimately made.",
    "Aurora's fiscal year ends March 31; 'Q1 FY2027' is the quarter ended 2026-06-30, reported 2026-08-05.",
    "Canadian LP with no US THC operations: US Schedule-III / 280E economics do not accrue to it directly, only sector sentiment beta.",
    "the float is heavily retail."
  ],
  "body_markdown": "## Current Thesis\nThe frame flipped on 2026-08-11. Aurora had been trading as sentiment beta to a US reschedule whose economics never reached a Canadian LP; it is now a take-over target with a named strategic bidder and published terms. Curaleaf announced its intention to bid for all Aurora common shares at an implied US$4.00 — 0.3463 Curaleaf subordinate voting shares plus US$0.75 cash — a 45% premium to Aurora's US$2.75 30-day VWAP, with the implied value capped at US$5.00. Aurora's board responded the same session by forming a special committee of independent directors and noting publicly that the US$5.00 cap sits below where its shares traded on 2025-12-18. Two trading halts hit the tape that day.\n\n## Bull Case\n- **Public terms from a named strategic bidder, 2026-08-11.** 0.3463 Curaleaf shares + US$0.75 cash, implied US$4.00, a 45% premium to the US$2.75 30-day VWAP; MJBizDaily and Investing News put the implied transaction value at roughly US$272M.\n- **The offer is thin against the balance sheet.** Aurora reported FY2026 on 2026-06-11 as debt-free with $165M cash. An implied ~US$272M equity value against that cash position is the arithmetic behind the board's inadequacy framing, and it makes a raised offer or a competing bidder a live possibility rather than a hopeful one.\n- **A two-month private negotiation preceded the public move.** Curaleaf's letters are dated 2026-06-23 and 2026-07-07 (only the July letter carried financial terms, since modified); Aurora disputed the \"refused to engage\" characterisation, citing lead-independent-director contact with Curaleaf CEO Boris Jordan as recently as 2026-07-24.\n- **Bottom line beat on the 2026-08-05 print.** Q1 FY2027 EPS -$0.05 versus -$0.13 consensus.\n- **The asset Curaleaf says it wants is compounding.** FY2026 (reported 2026-06-11): record global medical net revenue $289M, +18% YoY; adjusted EBITDA $54M, +32%; international medical $177M, with 55% of revenue outside Canada.\n\n## Bear Case\n- **No bid exists yet.** The 2026-08-11 Curaleaf release states no formal take-over bid has been commenced and there is no assurance the proposed offer is ultimately made. The premium in the tape is priced off a stated intention.\n- **Mostly acquirer paper, and capped.** US$0.75 per share is cash; the balance is Curaleaf subordinate voting stock, which trades on the TSX and OTCQX rather than a US national exchange because of Curaleaf's US plant-touching operations. The implied US$4.00 floats with Curaleaf's share price and the consideration value is capped at US$5.00 — Aurora's own 2026-08-11 statement flags that cap as below its 2025-12-18 trading level.\n- **Fundamentals kept softening into the bid.** Q1 FY2027 (2026-08-05) revenue $48.798M missed the $50.510M consensus and stepped down from $61.842M in Q4 FY2026. FY2027 is guided as a transitional year: total net revenue back toward FY2025 levels, adjusted gross margin easing to the mid-to-high 50s from 64%, on a ~30% Canadian medical reimbursement cut effective 2026-04-01.\n- **The policy leg stays dormant.** The DEA Schedule-III hearing closed ~2026-07-15 with no ALJ recommendation timeline, and the 2026-04-28 downschedule order covers state-medical and FDA-approved products — US-operator economics (280E relief), which a Canadian LP with no US THC operations does not collect.\n\n## Setup & Price Structure\n- 2026-08-14 close $3.68, 40.9% below the $6.23 52-week high; three-month return 10.8%, effectively all of it earned in one session.\n- RSI(14) 79.7 at that close. The move is one event gap, not accumulation across weeks.\n- Two halts on 2026-08-11 — a news-pending halt at 11:57 a.m. ET and a resumption notice at 4:15 p.m. ET. Stocktwits characterised the session as the biggest single-day rally in nearly 11 months.\n- that is the zone the tape reverts toward if the process lapses.\n- $3.68 trades below the US$4.00 implied consideration. The discount is what the market charges for an uncommenced, mostly-stock, value-capped hostile offer whose target board has already signalled the price is inadequate.\n- **The narrative is accelerating**, dated 2026-08-11 — fresh headlines, two halts, expanding participation off a base near the $2.75 VWAP, and a special committee that has not yet reported. Nothing in the flow yet resembles a crowded, late-cycle bid; equally, the entire narrative is four trading days old.\n\n## Catalyst Calendar (next 30 days)\n\n- **Undated, expected within weeks (est.)** — Curaleaf mailing a formal take-over bid circular. Under Canada's NI 62-104 a commenced bid must remain open for a minimum 105-day deposit period unless the target board reduces it to no fewer than 35 days.\n- **Within 15 days of any formal commencement (NI 62-104)** — Aurora directors' circular carrying the special committee's recommendation, and any shareholder rights plan adopted alongside it.\n- **~2026-11-05 (est.)** — Q2 FY2027 print, the next fundamental checkpoint on whether revenue stabilises above the $48.798M Q1 level.\n\n## Elapsed catalysts\n\n- **2026-08-17** — DEA Schedule-III post-hearing brief deadline. Sector sentiment only; an ALJ recommendation and administrator decision remain undated, so the date passing without a schedule leaves the policy leg where it was. *(passed 9d ago)*\n\n## What Would Change Our Mind\n- The process dying quietly is the main break: no circular mailed, the stated intention lapsing, and the premium having nothing to stand on. The gradeable version is a weekly close below $3.05, which gives back the bulk of the 2026-08-11 gap and reads as the market pricing a failed bid back toward the US$2.75 pre-announcement VWAP.\n- On the constructive side, a formal circular at terms above US$4.00, a competing bidder, or a special-committee recommendation of a negotiated deal converts a capped ceiling into a floor.\n- A Q2 FY2027 revenue print below $48.798M strengthens Curaleaf's argument that US$4.00 is full, and weakens any case for a raise.\n- If the stock chops between roughly $3.60 and $4.00 for several weeks with no circular and coverage thins, the narrative label moves toward maturing and the event premium bleeds without a price break.\n\n## Correlation Notes\n- Implied deal value is now mechanically linked to Curaleaf: at 0.3463 Curaleaf shares per Aurora share, a Curaleaf drawdown lowers the consideration, while a Curaleaf rally is truncated by the US$5.00 cap.\n- Residual beta to the US reschedule tape (MSOS, GTBIF, CURLF, TCNNF) persists, but the 280E economics accrue to US operators.\n- Canadian LP peers (TLRY, CGC, OGI) carry read-across risk from a first cross-border consolidation attempt at this scale.",
  "first_seen": "2026-04-23",
  "last_analyzed": "2026-08-16T13:19:59+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}